Celtic Biotech is pioneering the development of innovative cancer therapies utilizing natural peptides derived from snake venom, specifically targeting solid tumors and associated pain. Their lead product, CB-24 (crotoxin), is a potent neurotoxin that selectively induces programmed cell death in cancerous cells while sparing healthy cells. This mechanism is particularly significant for treating aggressive cancers such as non-small-cell lung cancer (NSCLC), which has historically poor outcomes. The company aims to enhance survival rates and improve the quality of life for cancer patients globally, making treatments more affordable and accessible.

The clinical trials conducted by Celtic Biotech have shown promising results, with several patients experiencing significant therapeutic benefits, including disease stabilization and remission. The therapies not only target cancer cells effectively but also provide substantial pain relief, which is a critical aspect of cancer treatment. The company is committed to further refining their treatment protocols and increasing dosage levels in upcoming trials to optimize efficacy. By focusing on the unique properties of venom-derived compounds, Celtic Biotech is positioned to revolutionize cancer treatment and address the unmet needs in oncology.

Ireland

Celtic Biotech is developing novel candidate therapies for the treatment of solid cancers and pain in humans. Derived from specialised receptor binding proteins found in snake venom, these product candidates have the potential to increase survival, improve quality-of-life and reduce treatment costs for cancer patients.

Celtic Biotech is focusing its research on solid tumours, including non-small-cell lung cancer (NSCLC), as its initial targets. The Company's lead candidate, CB24 (Crotoxin), has been observed to be highly toxic to various tumour cell lines in pre-clinical and early clinical studies.

Celtic Biotech

Company Details